Atovaquone Patent, Mast Cell Inflammatory Disease Treatment
Summary
Atovaquone Patent, Mast Cell Inflammatory Disease Treatment
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION FOR TREATING MAST CELL-MEDIATED INFLAMMATORY DISEASES
Application US20260097004A1 Kind: A1 Apr 09, 2026
Inventors
Lei CHU, Ethan A. LERNER, Vemuri B. REDDY, Yuping RAN
Abstract
The present disclosure relates to use of Atovaquone for treating and preventing acute and chronic inflammatory diseases in a mammal. The acute and chronic inflammatory diseases comprise mast cell-mediated inflammatory diseases.
CPC Classifications
A61K 31/122 A61P 37/06
Filing Date
2022-10-12
Application No.
19120757
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.